Jeena Sikho Lifecare
726.80
+9.90(+1.38%)
Market Cap₹9,034.18 Cr
PE Ratio263.73
IndustryHealthcare
Company Performance:
1D+1.38%
1M+2.48%
6M+31.12%
1Y-66.71%
5Y+319.27%
View Company Insightsright
More news about Jeena Sikho Lifecare
26Dec 25
Jeena Sikho Lifecare Expands Hospital Network Under Niva Bupa Empanelment
Jeena Sikho Lifecare Limited has executed an addendum with Niva Bupa Health Insurance Company Limited, expanding its empanelment arrangement to include additional hospital units across 20 locations nationwide. The addendum updates applicable tariff and commercial terms for newly empanelled units while maintaining existing terms for other facilities. The expanded network covers key cities across Punjab, Rajasthan, Maharashtra, Delhi NCR, Uttar Pradesh, and other states, enhancing accessibility for Niva Bupa policyholders.
26Dec 25
Jeena Sikho Lifecare Limited Gets Empanelled with Medsave Health Insurance TPA
Jeena Sikho Lifecare Limited announced its empanelment with Medsave Health Insurance TPA Limited, authorizing the company to provide cashless Ayurveda Panchkarma treatment to insured beneficiaries. The arrangement covers the company's extensive network of 44 hospitals across multiple states including key locations in Haryana, Maharashtra, Uttar Pradesh, Rajasthan, and other major cities, enhancing accessibility to specialized Ayurvedic treatments for insurance-covered patients.
26Dec 25
Jeena Sikho Lifecare Limited Gets Empanelled with Air India for Ayurveda Panchkarma Treatment Services
Jeena Sikho Lifecare Limited has been empanelled with Air India to provide cashless Ayurveda Panchkarma treatment services to Air India employees and eligible beneficiaries. The arrangement covers nine hospital locations across Delhi, Uttar Pradesh, and Haryana, and operates in the ordinary course of business without involving related party transactions or requiring additional material contract disclosures.
23Dec 25
Jeena Sikho Lifecare Limited Board Meeting Outcome: Internal Auditor Changes
Jeena Sikho Lifecare Limited conducted a board meeting on December 23, 2025, approving the resignation of M/s Deepak K Garg Associates as Internal Auditor and appointing M/s. Forvis Mazars LLP for FY 2025-26. The transition ensures continuity in internal audit processes while maintaining regulatory compliance with SEBI requirements.
12Nov 25
Jeena Sikho Lifecare Reports 66% Revenue Surge in Q2 FY26, Expands Bed Capacity to 2,802
Jeena Sikho Lifecare Limited, an alternative healthcare provider, reported strong Q2FY26 results. Revenue increased 66% year-on-year to Rs. 190.00 crores. Profit after tax surged 121% to Rs. 59.00 crores, while EBITDA grew 129% to Rs. 92.00 crores. The company expanded its bed capacity to 2,802 across 58 hospitals and 59 clinics in 23 states. A strategic partnership with Chandan Diagnostic was announced, providing access to 40 lakh privilege cardholders. The company plans to launch 10 new OTC products and has partnered with Salesforce for improved data management.
06Nov 25
Jeena Sikho Lifecare Reports Strong Q2 Growth with 66% YoY Revenue Increase
Jeena Sikho Lifecare Limited (JSLL) announced strong Q2 results with revenue up 66% YoY to ₹189.85 crore. EBITDA increased 129% to ₹92.06 crore, and PAT grew 121% to ₹58.78 crore. Patient volumes expanded significantly across IPD, OPD, and Day Care. The company added three new hospitals, increasing bed capacity to over 2,220. JSLL is focusing on the private business segment for better margins and has launched new OTC products. A partnership with Salesforce aims to enhance operational efficiency and patient engagement.
06Nov 25
Jeena Sikho Lifecare Reports 121% Net Profit Surge in Q2
Jeena Sikho Lifecare Limited (JSLL) reported impressive Q2 results with net profit rising 121% to ₹588.00 million. Revenue grew 67% to ₹1,898.50 million, while EBITDA more than doubled to ₹920.60 million. The company expanded its operational bed capacity to over 2,220 beds, with 400 more under development. JSLL is focusing on the private business segment for better margins and has launched new OTC products. A partnership with Salesforce aims to improve patient care and operational efficiency.
14Oct 25
Jeena Sikho Lifecare Expands Nationwide with Ayurvedic Detox Kit Launch
Jeena Sikho Lifecare Limited (JSLL) has launched its Pet Shuddhi product line nationally, introducing the Pet-Yakrit-Pleeha Shuddhi Kit, an Ayurvedic detox product for stomach, liver, and spleen. The product is available across India through JSLL's hospital network. Additionally, JSLL has entered into an exclusive diagnostic collaboration with Chandan Healthcare Limited, appointing them as the exclusive diagnostic partner for all Jeena Sikho facilities with a five-year lock-in period. This partnership aims to enhance JSLL's healthcare offerings by integrating diagnostic and preventive healthcare services.
13Oct 25
Jeena Sikho Lifecare Inks 5-Year Diagnostic Deal with Chandan Healthcare, Invests ₹42.12 Crore
Jeena Sikho Lifecare Limited has entered into a strategic partnership with Chandan Healthcare Limited, approved on October 13, 2025. The partnership includes a five-year exclusive diagnostic collaboration agreement and a significant investment. Chandan Healthcare will be the sole diagnostic partner for all Jeena Sikho's facilities. Jeena Sikho will invest up to ₹42.12 crore in Chandan Healthcare through convertible warrants. The collaboration aims to enhance diagnostic services quality and efficiency across Jeena Sikho's network.
24Sept 25
Jeena Sikho Lifecare Limited Launches New 230-Bed Hospital in Maharashtra's Raigad District
Jeena Sikho Lifecare Limited (JSLL) has launched operations at its new hospital in Raigad District, Maharashtra. The facility, located in Karnala village, spans 7.9 acres and features 230 beds, 54 rooms, and 3 OPD units. This expansion, completed in about five months since its proposal in April, marks a significant step in JSLL's growth strategy in Maharashtra's healthcare sector.
22Sept 25
Jeena Sikho Lifecare's MD Honored with 6th National Atal Award for Ayurveda Excellence
Acharya Manish Grover, Managing Director of Jeena Sikho Lifecare Limited (JSLL), received the 6th National Atal Award in the Indian Ayurveda category. The award, presented by the Atal Foundation at the Prime Minister Museum in New Delhi, recognizes Grover's contributions to revolutionizing Ayurveda-based industries, generating employment, and enhancing India's global economic presence. JSLL officially informed the National Stock Exchange of India Limited and BSE Limited about this achievement.
12Sept 25
Jeena Sikho Lifecare Expands Globally with UAE Subsidiary Amid Digital Transformation and Domestic Growth
Jeena Sikho Lifecare Limited has incorporated a wholly owned subsidiary in UAE, Jeena Sikho International LLC, with AED 100,000 investment. The company partnered with Salesforce for digital transformation in Ayurvedic healthcare. Additionally, it opened a new 40-bed hospital in Jammu, India, spanning 13,000 square feet.
12Sept 25
Jeena Sikho Lifecare Limited Expands Operations: New Hospital in Jammu and Digital Partnerships
Jeena Sikho Lifecare Limited (JSLL) has opened a new 40-bed hospital in Jammu, expanding its healthcare services. The facility spans 13,000 sq. ft. and includes 22 rooms and 2 OPDs. Additionally, JSLL has partnered with Salesforce and Quadrafort Technologies to implement digital changes in its Ayurvedic healthcare operations, signaling a commitment to modernization and improved efficiency.
08Sept 25
Jeena Sikho Lifecare Gains Approval for Anti-Diabetes Clinical Trials on Four Products
Jeena Sikho Lifecare has received approval for clinical trials on four anti-diabetes products: SDM02 Tablets, Shuddhi XS Syrup, Petshuddhi Churna, and Shuddhi Dr. B P Care Tablets. Initial trials show promising results in diabetes management without side effects. The company's multi-product approach aims to address various patient needs in diabetes care.
28Aug 25
Jeena Sikho Lifecare Limited Publishes Three New Chronic Kidney Disease Studies
Jeena Sikho Lifecare Limited has published three new case studies on chronic kidney disease management in academic journals, demonstrating significant patient improvements through integrated Ayurvedic treatments. The research shows measurable clinical outcomes including reduced blood urea levels from 230.86 mg/dL to 117.39 mg/dL and improved kidney function parameters across multiple patient cases.
27Aug 25
Jeena Sikho Lifecare Secures Exchange Approval for ESOP, Appoints New COO
Jeena Sikho Lifecare Limited has secured regulatory approvals from NSE and BSE for its Employee Stock Option Scheme 2025, covering up to 2,50,000 equity shares. The company also appointed Sahil Jain as COO and promoted Shreya Grover to Whole-Time Director, alongside approving a final dividend of ₹1.10 per share.
23Aug 25
Jeena Sikho Lifecare Unveils India's First Triple Detoxification Kit
Jeena Sikho Lifecare Limited has introduced the Pet-Yakrit-Pleeha Shuddhi Kit, India's first triple detoxification product for the gut, liver, and spleen. The launch took place at a press conference in Lucknow, featuring Acharya Manish Ji and Dr. Neha. The product is the result of over 20 years of research and clinical trials, targeting lifestyle-related diseases by addressing root causes. The company has informed both BSE and NSE about the launch through regulatory filings. Additionally, Jeena Sikho Lifecare is considering an Employee Stock Option Scheme, with a Board of Directors meeting scheduled to discuss this potential corporate action.
23Aug 25
Jeena Sikho Lifecare to Consider Employee Stock Option Scheme in Upcoming Board Meeting
Jeena Sikho Lifecare Limited (JSLL) has announced a board meeting on August 27 to consider and approve an Employee Stock Option Scheme (ESOS). The meeting will be held at the company's registered office in Zirakpur, Punjab. JSLL is listed on both NSE (JSLL) and BSE (544476). In a separate development, the company has been empaneled under CBSE to provide medical facilities at various branches, including Vaishali, Gurugram, Delhi, and Meerut.
19Aug 25
Jeena Sikho Lifecare Secures NABH Certification for Agra and Panchkula Hospitals, Releases Q1 FY 2025-26 Earnings Call Recording
Jeena Sikho Lifecare Limited (JSLL) has received NABH certifications for its facilities in Agra and Panchkula, valid until July 21, 2028. The company has made its Q1 FY 2025-26 earnings call recording available online. JSLL's Managing Director, Mr. Manish Grover, is set to attend the Systematix Group – Pharma & Healthcare Conference on August 21, 2025, in Mumbai.
16Aug 25
Jeena Sikho Lifecare Reports Robust 74% Revenue Growth in Q1 FY26
Jeena Sikho Lifecare Limited, an Ayurveda healthcare provider, reported impressive Q1 FY26 results. Revenue increased 74% to ₹174.29 crore, EBITDA grew 220% to ₹78.79 crore, and net profit rose 218% to ₹51.31 crore. The company saw significant growth in patient volumes across IPD, OPD, video consultations, and day care services. Strategic developments include adding 391 new beds, migrating to NSE and BSE mainboard, and launching a new product. Management remains focused on scaling Panchkarma services and driving growth in Medicines & OTC sales for FY26.
14Aug 25
Jeena Sikho Lifecare to Host Q1 FY2025-26 Earnings Conference Call on August 18
Jeena Sikho Lifecare Limited (JSLL) will host a conference call on August 18, 2025, at 4:00 PM IST to discuss Q1 FY2025-26 operational and financial performance. Managing Director Manish Grover and CFO Nanak Chand will lead the call. Dial-in numbers for various countries are provided. JSLL recently reported Q1 revenue of Rs. 17,428.59 lakhs and profit after tax of Rs. 5,131.14 lakhs. The company, which migrated to the Main Board of BSE/NSE on August 11, 2025, operates in Ayurvedic medicines and therapies.
13Aug 25
Jeena Sikho Lifecare Limited Publishes Ayurvedic Research Articles and Announces Investor Events
Jeena Sikho Lifecare Limited has published six research articles on Ayurvedic treatments for various health conditions. The company has scheduled an investor conference call on August 18, 2025, to discuss Q1 FY 2025-26 financial performance. Additionally, Managing Director Manish Grover will attend Antique's Flagship Investor Conference on August 20, 2025, in Mumbai.
26Jun 25
Jeena Sikho Lifecare Secures Approval for 'Shuddhi Dr. Madhumeh' Diabetes Tablet Clinical Trials
Jeena Sikho Lifecare has received approval to conduct clinical trials for its diabetes tablet, 'Shuddhi Dr. Madhumeh'. This marks a significant step in the company's efforts to develop innovative diabetes treatment solutions. The clinical trials will evaluate the safety and efficacy of the tablet, which is designed specifically for diabetic patients. This development could potentially impact the diabetes care landscape, offering new treatment options for millions affected by the condition worldwide.
Jeena Sikho Lifecare
726.80
+9.90
(+1.38%)
1 Year Returns:-66.71%
Industry Peers
Sun Pharmaceutical
1,698.00
(-1.78%)
Divis Laboratories
6,389.50
(-0.73%)
Torrent Pharmaceuticals
3,961.60
(+0.54%)
Cipla
1,430.20
(-1.25%)
Lupin
2,198.50
(+0.89%)
Dr Reddys Laboratories
1,183.30
(-0.67%)
Mankind Pharma
2,235.10
(+0.96%)
Zydus Life Science
888.40
(-1.37%)
Alkem Laboratories
5,816.00
(-0.81%)
Aurobindo Pharma
1,186.00
(+1.57%)